Amarin | AMRN - Pre Tax Profit


Amarin reported $-852K in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Alnylam Pharmaceuticals USD 161.14M 77.83M Dec/2025
Amarin USD -852K 7.26M Dec/2025
AstraZeneca USD 3.24B 117M Sep/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
DBV Technologies USD -33.16M 8.6M Sep/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
GlaxoSmithKline GBP 1.23B 1.23B Dec/2025
Halozyme Therapeutics USD 218.96M 14.02M Sep/2025
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Ionis Pharmaceuticals USD -228M 99M Dec/2025
Nektar Therapeutics USD -37.05M 15.27M Sep/2024
Neurocrine Biosciences USD 239.4M 52.4M Dec/2025
Novartis USD 4.64B 445M Dec/2025